| Patient | Pierre Le Moyne d'Iberville |
|---|---|
| Date of birth | 1982-07-16 |
| Identifiers | MRN HR-ET014-SYN; SSN (made up) 000-14-7260 |
| Document date | 2026-07-28 |
| Author | Marguerite Delacroix-Boateng, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Pre-travel visit for a naval deployment to French Guiana and the French Antilles. [S]
Mr. Le Moyne d'Iberville, now 44, returns for his pre-travel vaccines. The squadron is expected to sail early next year for the French Antilles and French Guiana, with weeks ashore near Cayenne and Kourou and possible river work inland, and he expects to be away for many months. He has had no fever since his malaria treatment four months ago. The PCR drawn at his last malaria review was negative. The forearm abscess healed within ten days; the culture grew methicillin-susceptible Staphylococcus aureus, and he needed no antibiotic. His screening tests from the preventive visit were negative for HIV and hepatitis C, and the hepatitis B panel shows he is not immune and has never been infected. He has no egg or gelatin allergy, no thymus disease, no immune-suppressing illness or treatment, and has never had yellow fever vaccine. [S]
| Element | Detail |
|---|---|
| Destination | French Antilles and French Guiana, many months, partly inland |
| Departure | Early next year |
| Malaria | No fever in four months |
| Screening | HIV and hepatitis C negative; not immune to hepatitis B |
| Vaccine screening | No contraindication to yellow fever vaccine |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight loss |
| Integumentary | Negative | Forearm healed; no other skin infections |
| Allergic and immunologic | Negative | No vaccine, egg or gelatin allergy; no immune disorder |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food | 1,000 mg, then 500 mg at 6, 24 and 48 hours (2,500 mg salt in total) | Oral route | 2026-03-03 to 2026-03-05 | completed | S |
| Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days | 30 mg base once daily for 14 days | Oral route | 2026-03-03 to 2026-03-16 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-28 | Body height | 175 | cm | S |
| 2026-07-28 | Body weight | 69.4 | kg | S |
| 2026-07-28 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 2026-07-28 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-07-28 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-07-28 | Heart rate | 66 | /min | S |
| 2026-07-28 | Respiratory rate | 14 | /min | S |
| 2026-07-28 | Body temperature | 36.7 | Cel | S |
| 2026-07-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Vital signs recorded on 2026-07-28; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; temperature 36.7 C, blood pressure 124/78, pulse 66, weight 69.4 kg |
| Right forearm | Small healed scar; no redness |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requested | resolved | confirmed | R50.9 | S — Synthetic presenting problem anchored to his documented recurrent attacks of illness called malaria; superseded by the diagnosis at the infectious diseases consultation. |
| Relapsing Plasmodium vivax malaria: P. vivax DNA detected by PCR in blood drawn between attacks, with negative smears and rapid antigen test; after three relapses treated without antirelapse therapy; normal quantitative G6PD | resolved | confirmed | B51.9 | S — Synthetic modern diagnosis made at the infectious diseases consultation, linked to his documented recurrent attacks of illness called malaria; the species and the PCR result are synthetic. |
| Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccines | active | confirmed | Z71.84 | S — Synthetic modern counterpart of his documented preparation of a tropical campaign in 1705. |
| Small cutaneous abscess of the right forearm, about 2 cm, from a wooden splinter in the dockyard, without fever, spreading cellulitis or systemic signs; drained, without antibiotics; methicillin-susceptible Staphylococcus aureus on culture; resolved | resolved | confirmed | L02.413 | S — Synthetic acute problem; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Yellow fever vaccine: indication, entry requirement, contraindications and precautions | Once, before travel | Completed today | Required for entry to French Guiana; no contraindication; age under 60; dose given and certificate issued |
| Examination | Hepatitis A, hepatitis B and typhoid vaccines | Before travel | Completed today | Hepatitis A dose 1, typhoid Vi and HepB-CpG dose 1 given |
| Examination | Rabies pre-exposure vaccination | Discuss before travel | Not indicated | Dogs with rabies are uncommon in French Guiana; rabies is present in bats. His duties are shipboard and coastal; after discussion he chose not to have it and knows to seek post-exposure care after any bite or scratch |
| Medication safety | Malaria chemoprophylaxis choice | Before travel | Due | To be prescribed at the pre-departure visit |
| Self-management | Relapse surveillance and the fever action plan | Every visit | Completed today | No fever in four months |
Goal progress:
Immunizations given today: Yellow fever vaccine, live, single dose; certificate (ICVP) issued, valid from ten days after vaccination; Hepatitis A vaccine, adult, dose 1 of 2; Typhoid Vi polysaccharide vaccine; Hepatitis B vaccine (HepB-CpG), dose 1 of 2 [S]
Guideline basis: CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Yellow Fever (2026); French Guiana (France): travel health destination page (yellow fever and malaria information updated April 2025) (2026); The practice of travel medicine: guidelines by the Infectious Diseases Society of America (Hill DR, et al. Clin Infect Dis 2006;43(12):1499-1539) (2006)
Follow-up: Pre-departure review in about eleven weeks. Next scheduled visit 2026-10-13: pre-departure review: no relapse, malaria chemoprophylaxis, vector, food and water precautions, standby treatment, and the plan on return. [S]